PAT Data Will Not Be Evaluated During Drug Inspections – FDA
This article was originally published in The Tan Sheet
Executive Summary
As a general policy, FDA will not look at process analytical technology research data during drug inspections, FDA New Jersey District Director Douglas Ellsworth asserted during a recent industry-sponsored conference